$0.88
3.49% today
NYSE, Apr 01, 06:51 pm CET
ISIN
US1420381089
Symbol
CRBU
Sector
Industry

Caribou Biosciences Stock price

$0.91
-0.26 21.96% 1M
-1.05 53.41% 6M
-0.68 42.57% YTD
-4.14 81.92% 1Y
-8.27 90.05% 3Y
-15.41 94.41% 5Y
-15.41 94.41% 10Y
NYSE, Closing price Mon, Mar 31 2025
-0.03 2.77%
ISIN
US1420381089
Symbol
CRBU
Sector
Industry

Key metrics

Market capitalization $84.92m
Enterprise Value $-98.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.69
EV/Sales (TTM) EV/Sales -9.82
P/S ratio (TTM) P/S ratio 8.50
P/B ratio (TTM) P/B ratio 0.33
Revenue growth (TTM) Revenue growth -71.01%
Revenue (TTM) Revenue $9.99m
EBIT (operating result TTM) EBIT $-166.62m
Free Cash Flow (TTM) Free Cash Flow $-143.08m
Cash position $209.54m
EPS (TTM) EPS $-1.65
P/E forward negative
P/S forward 9.30
EV/Sales forward negative
Short interest 9.93%
Show more

Is Caribou Biosciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Caribou Biosciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Caribou Biosciences forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Caribou Biosciences forecast:

Buy
88%
Hold
13%

Financial data from Caribou Biosciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
9.99 9.99
71% 71%
100%
- Direct Costs 3.93 3.93
38% 38%
39%
6.07 6.07
78% 78%
61%
- Selling and Administrative Expenses 39 39
49% 49%
386%
- Research and Development Expense 130 130
16% 16%
1,303%
-163 -163
48% 48%
-1,629%
- Depreciation and Amortization 3.93 3.93
38% 38%
39%
EBIT (Operating Income) EBIT -167 -167
44% 44%
-1,668%
Net Profit -149 -149
46% 46%
-1,493%

In millions USD.

Don't miss a Thing! We will send you all news about Caribou Biosciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Caribou Biosciences Stock News

Neutral
GlobeNewsWire
22 days ago
-- CB-010 ANTLER 2L LBCL and CB-011 CaMMouflage r/r MM Phase 1 clinical data expected in H1 2025 -- -- Advancing four clinical programs for hematologic malignancies and autoimmune diseases --
Neutral
GlobeNewsWire
26 days ago
NEW YORK, March 06, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASDAQ: CRBU) on behalf of long-term stockholders following a class action complaint that was filed against Caribou on December 24, 2024 with a Class Period from July 14, 2023 to July 16, 2024. Our inv...
Neutral
PRNewsWire
about one month ago
NEW YORK , Feb. 24, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Caribou Biosciences, Inc. (NASDAQ: CRBU) between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period"), of the important February 24, 2025 lead plaintiff deadline. So what: If you purchased Caribou securities during the Class Period you may be enti...
More Caribou Biosciences News

Company Profile

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Head office United States
CEO Rachel Haurwitz
Employees 147
Founded 2011
Website www.cariboubio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today